Galapagos Enters into Oncology Target Discovery Collaboration with Janssen Pharmaceutica
News Jan 04, 2008
BioFocus DPI will apply Galapagos’ proprietary adenoviral platform to identify drug targets for the development of cancer therapies.
The goal of the new collaboration will be to discover and validate novel targets in the field of oncology. BioFocus DPI will perform assay development, screening of the SilenceSelect® and FLeXSelect® adenoviral libraries, and target validation. Target discovery in in-vitro assays may provide drug targets for cancer areas with an unmet medical need.
BioFocus DPI receives an upfront payment of €2.9 million. In total, BioFocus DPI may receive additional research, acceptance, license and development fees of up to €7.6 million should certain predetermined criteria be achieved.
“This marks BioFocus DPI’s first target discovery agreement in oncology, as well as the largest target discovery agreement to date for the service division,” said Onno van de Stolpe, Chief Executive Officer of Galapagos.
Modified Form of Botox Could Replace Opioids as Treatment for Chronic PainNews
A modified form of botulinum toxin gives long-lasting pain relief in mice without adverse effects and, in time, could replace opioid drugs as a safe and effective way of treating chronic pain, according to new research.READ MORE
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
Tackling Cancer at Ground Zero: Designer Molecule Inhibits Protein TargetNews
A new molecule designed by University of Adelaide researchers shows great promise for future treatment of many cancers. The new molecule successfully targets a protein that plays a major role in the growth of most cancers.READ MORE
5th edition of the International Conference Clinical Oncology and Molecular Diagnostics
Jun 17 - Jun 18, 2019